Cytokinetics inc stock
WebCytokinetics started at overweight with $58 stock price target at J.P. Morgan. Dec. 10, 2024 at 6:59 a.m. ET by Tomi Kilgore. Biotech and Pharma Cytokinetics Stock Is … WebMar 31, 2024 · Cytokinetics Inc's market capitalization is $4.08 B by 94.63 M shares outstanding. Is Cytokinetics stock a Buy, Sell or Hold? Cytokinetics stock has …
Cytokinetics inc stock
Did you know?
WebPipeline - Cytokinetics A pipeline powered by passion pipeline Research Pre-Clinical Phase 1 Phase 2 Phase 3 CARDIAC MUSCLE Omecamtiv Mecarbil (Heart Failure) Aficamten (oHCM) Aficamten (nHCM) CK-136 … WebGet the latest Cytokinetics, Inc. (KK3A) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment …
WebNov 29, 2024 · Cytokinetics, Inc. (CYTK) stock has gained 0.67% while the S&P 500 has fallen -0.43% as of 11:42 AM on Tuesday, Nov 29. CYTK is higher by $0.27 from the previous closing price of $40.09 on volume of 312,812 shares. Over the past year the S&P 500 is lower by -15.22% while CYTK is higher by 4.10%. Web1 day ago · Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle …
WebApr 9, 2024 · In other Cytokinetics news, CEO Robert I. Blum sold 12,500 shares of the stock in a transaction on Monday, March 6th. The stock was sold at an average price of … WebApr 10, 2024 · Zacks Equity Research. April 10, 2024, 9:23 AM · 3 min read. It has been a rough year so far for late-stage biopharmaceutical company, Cytokinetics, Incorporated CYTK. Shares of the company have ...
WebOTCFX - T. Rowe Price Small-Cap Stock Fund, Inc. This fund is a listed as child fund of Price T Rowe Associates Inc /md/ and if that institution has disclosed ownership in this security, then these positions will not be double counted when calculating total shares and total value: 195,000 : 8,935: 2024-12-21: NP
WebFind real-time CYTK - Cytokinetics Inc stock quotes, company profile, news and forecasts from CNN Business. ... Cytokinetics Inc (NASDAQ:CYTK) Real-Time Quotes. 35.41. … trying new physical activitiesWebApr 7, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors. Investors & Media Cytokinetics’ unparalleled expertise has kept it at the forefront of drug discovery and development for diseases impacting muscle performance. trying next serverWebApr 10, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential... phill brooksWebApr 6, 2024 · Cytokinetics (NASDAQ:CYTK) has a market capitalization of $3.48 billion and generates $94.59 million in revenue each year. The biopharmaceutical company earns … phill branchWebCytokinetics Stock Forecast & Predictions: 1Y Price Target $57.64 Buy or Sell NASDAQ: CYTK 2024 WallStreetZen Cytokinetics Inc Stock Forecast, Predictions & Price Target Overview Forecast Earnings Dividend Ownership Analyst price target for CYTK All Analysts Top Analysts phill bradyWebTHIS COMMON STOCK PURCHASE AGREEMENT (the “Agreement”) is made as of June 11, 2013 (the “Execution Date”) by and between Cytokinetics, Incorporated, a Delaware … trying new things in the new yearWebCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors. Investors & Media Cytokinetics’ unparalleled expertise has … phill calvert